FUJIFILM INTRODUCES SECOND GENERATION OF CR-BASED FFDM

Delivers same exceptional image quality with enhanced features and upgraded technologist workstation

  

Chicago, IL - November 29, 2009 - FUJIFILM Medical Systems USA, Inc., the world leader in Full Field Digital Mammography (FFDM) with over 7,000 systems sold, is pleased to announce the second generation of its CR-based FFDM system, the Aspire ClearView1 reader. The new system, which comes complete with an enhanced technologist acquisition workstation (AWS-c1), marks the evolution of the only FDA approved CR-based mammography solution available in the US.

“Fujifilm’s dedication to the continued evolution of its FFDM product line reinforces the company’s confidence in CR-based mammography as a high quality, scalable solution for breast screening facilities across the country,” stated Jeanine Rader, Fujifilm’s Director and General Manager, Women’s Health. “We are not just the first company to bring CR-based FFDM to the U.S. market, but now also the first to enhance this highly reliable breast imaging technology, further strengthening our world-wide leadership position as a women’s health company.”

The new Aspire ClearView will continue to provide Fujifilm’s legacy 50 micron resolution and dual-side reading technology delivering the exceptional image quality that is so important in mammography. The system’s enhancements include a sleeker design, lighter weight and a wider viewing angle on the LCD offering additional flexibility for room placement. ClearView will continue to be offered in a single slot and four-slot design. ClearView remains the only approved FFDM that can perform general x-ray imaging.

The latest evolution of the Aspire ClearView will come complete with a new acquisition workstation, the AWS-c, which will be the first color workstation available for technologists. This new workstation offers technologists an improved graphic user interface (GUI) with a full color, high brightness, 2 mega pixel LCD monitor in portrait format for quick recognition of important patient and exposure information. The new GUI also delivers Fujifilm’s efficient three-step workflow to maximize patient throughput and renowned algorithms, Image Intelligence™. Fujifilm’s user-friendly technologist GUI will be available with both the AWS-c and the AWS-d2, the workstation that will be paired with Fujifilm’s new Aspire HD2, DR-based FFDM system. This will provide consistency across product lines for a streamlined workflow and greater efficiency for the user of either of Fujifilm’s FFDM offerings. Also available for the first time is an optional high resolution, 3 mega pixel or 5 mega pixel, greyscale companion monitor for quick confirmation of the acquired image.

The new Aspire ClearView readers are expected to be available in the first half of 2010. The AWS-c will be commercially available upon receipt of FDA approval.

For more information visit Fujifilm at RSNA booth #6238 located in the South Hall.

About FUJIFILM Medical Systems USA, Inc.
FUJIFILM Medical Systems USA, Inc. is one of the FUJIFILM Corporation family of companies with 70 years of imaging experience and more than $28 billion in sales. Its extensive portfolio includes diagnostic imaging products and informatics solutions to meet the needs of healthcare facilities in both outpatient and hospital settings. A worldwide leader in mammography with over 7,000 installations, Fujifilm provides the Aspire™ line of versatile and scalable women’s healthcare solutions for acquiring, processing and managing digital data in any imaging environment. Fujifilm’s Aspire products help deliver quality patient care through increased efficiency and improved productivity with the lowest cost of ownership. FUJIFILM Medical Systems USA is headquartered in Stamford, CT.

1Known as the PROFECT outside the U.S. The new Aspire ClearView and the AWS-c are not yet available for sale in the U.S.

2The Aspire HD is known as the AMULET outside the U.S. Both the Aspire HD and the AWS-d require FDA approval and are not yet available for sale in the U.S.